You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(9.10)︱新鴻基地產年度純利跌47.6%至235.21億港元;君實生物特瑞普利單抗注射液用於鼻咽癌的治療獲得FDA突破性療法認定
格隆匯 09-10 23:10

【財務數據】

新鴻基地產(00016.HK)年度純利減少47.6%至235.21億港元 末期息3.7港元

濠亮環球(08118.HK)一季度純利593.5萬港元 同比增長9.3%

【業績預告】

易緯集團(03893.HK)預計年度虧損擴大至2800萬-3000萬港元

威鋮國際(01002.HK)預期年度虧損減少約72%

【運營數據】

綠地香港(00337.HK)首8月合約銷售約195.12億元

華電福新(00816.HK)8月完成總髮電量551.01萬兆瓦時 同比增加26.9%

寶勝國際(03813.HK)8月綜合經營收益淨額跌7.2%至20.71億元

裕元集團(00551.HK):8月綜合經營收益淨額約6.26億美元

友佳國際(02398.HK):前8月銷售額約5.27億元 同比下跌13%

華潤電力(00836.HK)附屬電廠8月售電量同比增加10.4%

【股權變更】

王朝酒業(00828.HK):控股股東恆名全部股權完成轉讓予天津食品

【併購出售】

中興通訊(00763.HK):子公司擬受讓集成電路產業基金所持微電子24%股權

中植資本國際(08295.HK)擬8.5億元收購KingNine Holdings全部股權

【要約私有化】

均安控股(01559.HK)獲華冠集團溢價41.94%提要約收購 明日復牌

【重大事項】

浙江世寶(01057.HK)正式成為長安福特轉向器合格供應商

復星醫藥(02196.HK):用於晚期乳腺癌適應症治療新藥啟動II期臨牀研究

君實生物(01877.HK)特瑞普利單抗注射液用於鼻咽癌的治療獲得FDA突破性療法認定

科通芯城(00400.HK):科通工業獲戰投1.66億元 持股降至70.15%

HYPEBEAST(00150.HK)與日本大型娛樂集團旗下公司簽訂策略合作備忘錄

皇璽餐飲集團(08300.HK):獲香港放債人牌照

中國交通建設(01800.HK)成立項目公司投資唐山市全域治水清水潤城縣區工程PPP項目

卓悦控股(00653.HK)擬投資一間新加坡社交商務軟件初創企業

【回購註銷】

上海電氣(02727.HK)9月10日耗資3733.10萬港元回購1634.8萬股H股

中國旺旺(00151.HK)9月10日耗資6505.05萬港元回購1200萬股

天福(06868.HK)9月10日耗資398.5萬港元回購75.9萬股

金鷹商貿集團(03308.HK)9月10日耗資233.1萬港元回購33.1萬股

雷蛇(01337.HK)9月10日耗資251.93萬港元回購162萬股

合生創展集團(00754.HK)9月10日耗資163.2萬港元回購10萬股

康臣藥業(01681.HK)9月10日耗資177.06萬港元回購49.9萬股

中國水務(00855.HK)9月10日耗資136.74萬港元回購23萬股

富智康集團(02038.HK)9月10日耗資135.3萬港元回購150萬股

股權激勵】

世紀睿科(01450.HK)授出700萬份購股權

【人事任免】

招商銀行(03968.HK)選舉繆建民任董事長

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account